This section of the website is for UK Healthcare Professionals only. 
If you are not a Healthcare Professional, please click here.

IQIRVO® (elafibranor) therapeutic indication1

IQIRVO is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.1

IQIRVO dosing

IQIRVO dosing

A once-daily tablet for all eligible patients – with no dose adjustment1

Recommended dose:

  • Once-daily 80 mg dose, taken orally in adults with PBC, with or without food
  • The tablet should not be crushed, chewed or split prior to administration.
Recommended dose:

No dose adjustment required:

  • For patients with renal impairment
  • For patients over 65 years of age
  • For patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment
No dose adjustment required:

Hepatic impairment

  • Use in patients with severe hepatic impairment (Child-Pugh C) is not recommended
  • Prior to initiation of treatment with IQIRVO the patient’s hepatic status must be known.
Hepatic impairment

In case of a missed dose:

  • Patients should take the subsequent dose at the next scheduled time point. They should not take a double dose to make up for a missed dose
In case of a missed dose:

For full list of posology and dosing information, please refer to the SMPC before prescribing IQIRVO.

Abbreviation

PBC, primary biliary cholangitis.

Reference

  1. IQIRVO® (elafibranor) Summary of product characteristics (SmPC). 2024.